Our results (Fig. 3) confirmed that ultra low doses of RFA induce modulation of immune-relevant molecules within the tumor, resulting in a cascade of CEA-specific CD4+ T-cell immune responses. The gene discussed is CEACAM5; the disease is neoplasm.